Evusheld
(asked on 13th June 2022) - View Source
Question to the Department of Health and Social Care:
To ask Her Majesty's Government what estimate they have made of the number of immunocompromised individuals who would benefit from access to Evusheld if it became available.
This question was answered on 27th June 2022
Urgent work is underway with clinical experts to estimate the size of the cohort. The Therapeutics Clinical Review Panel provides advice on the most appropriate patient cohorts for new COVID-19 therapies, including preventative treatments. Final clinical policies and eligibility would be proposed by the National Health Service and agreed by the United Kingdom Chief Medical Officers.